Satellos Bioscience (NASDAQ:MSLE) Posts Earnings Results, Misses Expectations By $0.11 EPS

Satellos Bioscience (NASDAQ:MSLE) posted its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11), Zacks reports.

Satellos Bioscience Stock Down 10.7%

MSLE traded down $0.74 during trading on Friday, hitting $6.19. The stock had a trading volume of 124,882 shares, compared to its average volume of 123,285. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39. The company has a market cap of $95.70 million, a price-to-earnings ratio of -5.16 and a beta of 1.10.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on MSLE shares. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating for the company. Weiss Ratings began coverage on Satellos Bioscience in a report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Finally, Wall Street Zen downgraded shares of Satellos Bioscience to a “strong sell” rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Satellos Bioscience currently has an average rating of “Hold”.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.